{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:10:15Z","timestamp":1790493015874,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.vaccine.2009.12.083","type":"journal-article","created":{"date-parts":[[2010,1,21]],"date-time":"2010-01-21T09:29:45Z","timestamp":1264066185000},"page":"2259-2270","source":"Crossref","is-referenced-by-count":102,"title":["The second Geneva Consensus: Recommendations for novel live TB vaccines"],"prefix":"10.1016","volume":"28","author":[{"given":"K.B.","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Eskola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Thiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dobbelaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Grode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Fruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.H.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.12.083_bib1","series-title":"Global tuberculosis control. Epidemiology, strategy, financing. WHO Report 2009","year":"2009"},{"key":"10.1016\/j.vaccine.2009.12.083_bib2","unstructured":"Aeras Tuberculosis Vaccine Candidates. http:\/\/www aeras org\/our-approach\/vaccine-development php?portfolio; 2009."},{"issue":"Jun (3)","key":"10.1016\/j.vaccine.2009.12.083_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.coi.2009.05.017","article-title":"Tuberculosis vaccine research: the impact of immunology","volume":"21","author":"Barker","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"Mar (11\u201312)","key":"10.1016\/j.vaccine.2009.12.083_bib4","first-page":"156","article-title":"Vaccine strategies against tuberculosis","volume":"139","author":"McShane","year":"2009","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.vaccine.2009.12.083_bib5","doi-asserted-by":"crossref","first-page":"b1291","DOI":"10.1136\/bmj.b1291","article-title":"Eradication of tuberculosis by 2050 impossible without new vaccine","volume":"338","author":"Smith","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2009.12.083_bib6","unstructured":"TBVAC.org - Candidates. http:\/\/www tb-vac org\/works htm; 2009."},{"issue":"May (4)","key":"10.1016\/j.vaccine.2009.12.083_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/icb.2009.14","article-title":"TB vaccines: current status and future perspectives","volume":"87","author":"Aagaard","year":"2009","journal-title":"Immunol Cell Biol"},{"issue":"May (29)","key":"10.1016\/j.vaccine.2009.12.083_bib8","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1016\/j.vaccine.2005.03.001","article-title":"New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development","volume":"23","author":"Kamath","year":"2005","journal-title":"Vaccine"},{"issue":"May (5419)","key":"10.1016\/j.vaccine.2009.12.083_bib9","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","article-title":"Comparative genomics of BCG vaccines by whole-genome DNA microarray","volume":"284","author":"Behr","year":"1999","journal-title":"Science"},{"issue":"Feb (7\u20138)","key":"10.1016\/j.vaccine.2009.12.083_bib10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0264-410X(98)00277-1","article-title":"A historical and molecular phylogeny of BCG strains","volume":"17","author":"Behr","year":"1999","journal-title":"Vaccine"},{"issue":"Mar (13)","key":"10.1016\/j.vaccine.2009.12.083_bib11","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1073\/pnas.0700869104","article-title":"Genome plasticity of BCG and impact on vaccine efficacy","volume":"104","author":"Brosch","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Jun (2)","key":"10.1016\/j.vaccine.2009.12.083_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/1097-0061(20000630)17:2<111::AID-YEA17>3.0.CO;2-G","article-title":"Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur","volume":"17","author":"Brosch","year":"2000","journal-title":"Yeast"},{"issue":"Mar (6)","key":"10.1016\/j.vaccine.2009.12.083_bib13","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1073\/pnas.052548299","article-title":"A new evolutionary scenario for the Mycobacterium tuberculosis complex","volume":"99","author":"Brosch","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Feb (2)","key":"10.1016\/j.vaccine.2009.12.083_bib14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14712598.8.2.201","article-title":"Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials","volume":"8","author":"Asensio","year":"2008","journal-title":"Expert Opin Biol Ther"},{"issue":"Sep (9)","key":"10.1016\/j.vaccine.2009.12.083_bib15","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin","volume":"115","author":"Grode","year":"2005","journal-title":"J Clin Invest"},{"issue":"Nov (10)","key":"10.1016\/j.vaccine.2009.12.083_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1086\/592450","article-title":"A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers","volume":"198","author":"Hoft","year":"2008","journal-title":"J Infect Dis"},{"issue":"Jan (4)","key":"10.1016\/j.vaccine.2009.12.083_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.vaccine.2005.08.001","article-title":"Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity","volume":"24","author":"Horwitz","year":"2006","journal-title":"Vaccine"},{"issue":"Aug (4)","key":"10.1016\/j.vaccine.2009.12.083_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1586\/14760584.4.4.541","article-title":"Tuberculosis: from genome to vaccine","volume":"4","author":"de Jonge","year":"2005","journal-title":"Expert Rev Vaccines"},{"issue":"Sep (1)","key":"10.1016\/j.vaccine.2009.12.083_bib19","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1371\/journal.ppat.0010005","article-title":"Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis","volume":"1","author":"Gutierrez","year":"2005","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2009.12.083_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/1471-2164-9-413","article-title":"Novel genome polymorphisms in BCG vaccine strains and impact on efficacy","volume":"9","author":"Leung","year":"2008","journal-title":"BMC Genomics"},{"issue":"Feb (2)","key":"10.1016\/j.vaccine.2009.12.083_bib21","article-title":"BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy","volume":"5","author":"Liu","year":"2009","journal-title":"Hum Vaccin"},{"issue":"Dec (4)","key":"10.1016\/j.vaccine.2009.12.083_bib22","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.shpsc.2005.09.003","article-title":"The \u2018experimental stable\u2019 of the BCG vaccine: safety, efficacy, proof, and standards, 1921\u20131933","volume":"36","author":"Bonah","year":"2005","journal-title":"Stud Hist Philos Biol Biomed Sci"},{"issue":"Sep (5)","key":"10.1016\/j.vaccine.2009.12.083_bib23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.socscimed.2008.05.016","article-title":"BCG vaccination and WHO's global strategy for tuberculosis control 1948\u20131983","volume":"67","author":"Brimnes","year":"2008","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.vaccine.2009.12.083_bib24","unstructured":"BCG vaccine, freeze-dried\u2014Vaccinum tuberculosis (BCG) cryodesiccatum. European Pharmacopoeia; 2009. Report No.: 01\/2008:0163."},{"key":"10.1016\/j.vaccine.2009.12.083_bib25","series-title":"WHO requirements for dried BCG vaccine","author":"WHO","year":"1987"},{"key":"10.1016\/j.vaccine.2009.12.083_bib26","unstructured":"BCG for immunotherapy\u2014BCG ad immunocurationem. European Pharmacopoeia; 2009. Report No.: 01\/2009:1929."},{"issue":"6","key":"10.1016\/j.vaccine.2009.12.083_bib27","first-page":"1","article-title":"Multiproduct manufacturing facilities","volume":"26","year":"2006","journal-title":"Genet Eng Biotechnol News"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2009.12.083_bib28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt0593-561","article-title":"Multiuse biopharmaceutical manufacturing","volume":"11","author":"Hamers","year":"1993","journal-title":"Biotechnology"},{"issue":"Dec (12)","key":"10.1016\/j.vaccine.2009.12.083_bib29","first-page":"906","article-title":"Experimental research on utilization of bioluminescent technique to substitute the current viability count for BCG vaccine","volume":"102","author":"Chen","year":"1989","journal-title":"Chin Med J (Engl)"},{"issue":"Aug (36)","key":"10.1016\/j.vaccine.2009.12.083_bib30","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1016\/j.vaccine.2008.06.026","article-title":"Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine","volume":"26","author":"Ho","year":"2008","journal-title":"Vaccine"},{"issue":"Sep (5)","key":"10.1016\/j.vaccine.2009.12.083_bib31","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.biologicals.2008.05.001","article-title":"Development and validation of an ATP method for rapid estimation of viable units in lyophilised BCG Danish 1331 vaccine","volume":"36","author":"Jensen","year":"2008","journal-title":"Biologicals"},{"issue":"May (19)","key":"10.1016\/j.vaccine.2009.12.083_bib32","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0264-410X(99)00023-7","article-title":"Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines","volume":"17","author":"Kairo","year":"1999","journal-title":"Vaccine"},{"issue":"Jul (7)","key":"10.1016\/j.vaccine.2009.12.083_bib33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/CVI.00067-09","article-title":"Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis","volume":"16","author":"Parra","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"Sep (Suppl. 3)","key":"10.1016\/j.vaccine.2009.12.083_bib34","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1086\/314071","article-title":"Animal models for experimental tuberculosis","volume":"31","author":"Smith","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2009.12.083_bib35","doi-asserted-by":"crossref","first-page":"e5528","DOI":"10.1371\/journal.pone.0005528","article-title":"Analysis of Mycobacterium tuberculosis-specific CD8 T-Cells in patients with active tuberculosis and in individuals with latent infection","volume":"4","author":"Caccamo","year":"2009","journal-title":"PLoS ONE"},{"issue":"Oct (22)","key":"10.1016\/j.vaccine.2009.12.083_bib36","doi-asserted-by":"crossref","first-page":"12210","DOI":"10.1073\/pnas.210391497","article-title":"Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis","volume":"97","author":"Cho","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Dec (12)","key":"10.1016\/j.vaccine.2009.12.083_bib37","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1002\/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4","article-title":"Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells","volume":"30","author":"van Pinxteren","year":"2000","journal-title":"Eur J Immunol"},{"issue":"Dec (12)","key":"10.1016\/j.vaccine.2009.12.083_bib38","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1128\/IAI.68.12.7144-7148.2000","article-title":"Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia","volume":"68","author":"Smith","year":"2000","journal-title":"Infect Immun"},{"issue":"Dec (24)","key":"10.1016\/j.vaccine.2009.12.083_bib39","doi-asserted-by":"crossref","first-page":"12013","DOI":"10.1073\/pnas.89.24.12013","article-title":"Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection","volume":"89","author":"Flynn","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Apr (4)","key":"10.1016\/j.vaccine.2009.12.083_bib40","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/IAI.71.4.1672-1679.2003","article-title":"A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis","volume":"71","author":"Horwitz","year":"2003","journal-title":"Infect Immun"},{"issue":"May (5\u20136)","key":"10.1016\/j.vaccine.2009.12.083_bib41","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.micinf.2005.04.002","article-title":"Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins","volume":"7","author":"Horwitz","year":"2005","journal-title":"Microbes Infect"},{"issue":"Mar (10)","key":"10.1016\/j.vaccine.2009.12.083_bib42","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.vaccine.2005.10.002","article-title":"A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG","volume":"24","author":"Horwitz","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.12.083_bib43","unstructured":"Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers. ClinicalTrials.gov; 2009. Report No.: NCT00749034."},{"issue":"Feb (4)","key":"10.1016\/j.vaccine.2009.12.083_bib44","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.4049\/jimmunol.168.4.1869","article-title":"Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guerin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy","volume":"168","author":"Grode","year":"2002","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2009.12.083_bib45","doi-asserted-by":"crossref","first-page":"e3496","DOI":"10.1371\/journal.pone.0003496","article-title":"PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence","volume":"3","author":"Gonzalo-Asensio","year":"2008","journal-title":"PLoS One"},{"issue":"Nov (11)","key":"10.1016\/j.vaccine.2009.12.083_bib46","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.tim.2008.08.006","article-title":"PhoP, a key player in Mycobacterium tuberculosis virulence","volume":"16","author":"Ryndak","year":"2008","journal-title":"Trends Microbiol"},{"issue":"Apr (18)","key":"10.1016\/j.vaccine.2009.12.083_bib47","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/j.vaccine.2009.02.060","article-title":"Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant","volume":"27","author":"Cardona","year":"2009","journal-title":"Vaccine"},{"issue":"Jan (1)","key":"10.1016\/j.vaccine.2009.12.083_bib48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.micinf.2008.10.013","article-title":"Intracellular replication of attenuated Mycobacterium tuberculosis phoP mutant in the absence of host cell cytotoxicity","volume":"11","author":"Ferrer","year":"2009","journal-title":"Microbes Infect"},{"issue":"Apr (17)","key":"10.1016\/j.vaccine.2009.12.083_bib49","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.vaccine.2006.03.017","article-title":"The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs","volume":"24","author":"Martin","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2009.12.083_bib50","doi-asserted-by":"crossref","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","article-title":"MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques","volume":"4","author":"Verreck","year":"2009","journal-title":"PLoS One"},{"issue":"Jul (34)","key":"10.1016\/j.vaccine.2009.12.083_bib51","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2009.05.050","article-title":"Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates","volume":"27","author":"Larsen","year":"2009","journal-title":"Vaccine"},{"issue":"Oct (10)","key":"10.1016\/j.vaccine.2009.12.083_bib52","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/nm765","article-title":"A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis","volume":"8","author":"Sambandamurthy","year":"2002","journal-title":"Nat Med"},{"issue":"May (5\u20136)","key":"10.1016\/j.vaccine.2009.12.083_bib53","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.micinf.2005.04.001","article-title":"Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis","volume":"7","author":"Sambandamurthy","year":"2005","journal-title":"Microbes Infect"},{"issue":"Feb (2)","key":"10.1016\/j.vaccine.2009.12.083_bib54","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1128\/IAI.73.2.1196-1203.2005","article-title":"Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis","volume":"73","author":"Sambandamurthy","year":"2005","journal-title":"Infect Immun"},{"issue":"Sep (37\u201339)","key":"10.1016\/j.vaccine.2009.12.083_bib55","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1016\/j.vaccine.2006.05.097","article-title":"Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis","volume":"24","author":"Sambandamurthy","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.12.083_bib56","doi-asserted-by":"crossref","first-page":"a2052","DOI":"10.1136\/bmj.a2052","article-title":"Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial","volume":"337","author":"Hawkridge","year":"2008","journal-title":"BMJ"},{"issue":"Feb (2)","key":"10.1016\/j.vaccine.2009.12.083_bib57","first-page":"88","article-title":"BCG vaccination in South African HIV-exposed infants\u2014risks and benefits","volume":"99","author":"Hesseling","year":"2009","journal-title":"S Afr Med J"},{"key":"10.1016\/j.vaccine.2009.12.083_bib58","series-title":"Guidelines on clinical evaluation of vaccines: regulatory expectations","author":"WHO","year":"2004"},{"key":"10.1016\/j.vaccine.2009.12.083_bib59","series-title":"Guideline for good clinical practice","year":"1996"},{"issue":"Jul (7)","key":"10.1016\/j.vaccine.2009.12.083_bib60","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1371\/journal.pmed.0050145","article-title":"Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations","volume":"5","author":"Hanekom","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2009.12.083_bib61","series-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","year":"2008"},{"key":"10.1016\/j.vaccine.2009.12.083_bib62","series-title":"ICH harmonised tripartite guideline: clinical investigation of medicinal products in the pediatric population","year":"2000"},{"key":"10.1016\/j.vaccine.2009.12.083_bib63","unstructured":"International Ethical Guidelines for Biomedical Research Involving Human Subjects. http:\/\/www cioms ch\/frame_guidelines_nov_2002 htm; 2002."},{"key":"10.1016\/j.vaccine.2009.12.083_bib64","unstructured":"CFR21:50. Protection of Human Subjects. https:\/\/www accessdata fda gov\/scripts\/cdrh\/cfdocs\/cfCFR\/CFRSearch cfm?CFRPart=50; 2009CFR Title 21: Chapter 1: Part 50."},{"key":"10.1016\/j.vaccine.2009.12.083_bib65","unstructured":"Pediatric Research Equity Act of 2003. ftp resource org\/gpo gov\/laws\/108\/publ155 108 pdf; 2003 Instrument Number:108\u2013155. GLIN ID: 175685."},{"key":"10.1016\/j.vaccine.2009.12.083_bib66","unstructured":"Directive 2001\/18\/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90\/220\/EEC - Commission Declaration. 2001. Report No.: Directive 2001\/18\/EC of the European Parliament."},{"key":"10.1016\/j.vaccine.2009.12.083_bib67","unstructured":"Guideline on Environmental Risk Assessments for Medicinal Products Consisting of, or Containing, Genetically Modified Organisms (GMOs). http:\/\/www emea europa eu\/pdfs\/human\/bwp\/47319106en pdf; 2006."},{"key":"10.1016\/j.vaccine.2009.12.083_bib68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-59745-379-0_19","article-title":"GM risk assessment","volume":"478","author":"Sparrow","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2009.12.083_bib69","series-title":"Guidance document of the scientific panel on genetically modified organisms for the risk assessment of genetically modified microorganisms and their derived products intended for food and feed use","year":"2009"},{"key":"10.1016\/j.vaccine.2009.12.083_bib70","series-title":"Electronic submissions for regulatory approval","year":"2004"},{"key":"10.1016\/j.vaccine.2009.12.083_bib71","unstructured":"History and Future of ICH: A brief History of ICH. The Need to Harmonise. http:\/\/www ich org\/cache\/compo\/276-254-1 html; 2009."},{"key":"10.1016\/j.vaccine.2009.12.083_bib72","unstructured":"Council Directive 65\/65\/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products. http:\/\/eur-lex europa eu\/LexUriServ\/LexUriServ do?uri=CELEX:31965L0065:EN:HTML; 1965."},{"key":"10.1016\/j.vaccine.2009.12.083_bib73","series-title":"Development and control of medicines and medical devices","author":"Harman","year":"2004"},{"key":"10.1016\/j.vaccine.2009.12.083_bib74","unstructured":"EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use Annex 19 Reference and Retention Samples. http:\/\/ec europa eu\/enterprise\/pharmaceuticals\/eudralex\/vol-4\/pdfs-en\/2005_12_14_annex19 pdf; 2005 December 14:1\u20135."},{"key":"10.1016\/j.vaccine.2009.12.083_bib75","unstructured":"General Requirements for the Production and Control of Live Mammalian Bacterial and Viral Vaccines for Veterinary Use. http:\/\/www emea europa eu\/pdfs\/vet\/vetguidelines\/7blm1a pdf; 2009."},{"key":"10.1016\/j.vaccine.2009.12.083_bib76","unstructured":"Guidance for Manufacturers on Clinical Investigations to be carried out in the UK. http:\/\/www mhra gov uk\/Publications\/Regulatoryguidance\/Devices\/GuidanceontheECMedicalDevicesDirectives\/CON007504; 2006 October 1:1\u201344."},{"key":"10.1016\/j.vaccine.2009.12.083_bib77","unstructured":"Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials. http:\/\/ec europa eu\/enterprise\/pharmaceuticals\/eudralex\/vol-10\/guidance-on-imp_nimp_04-2007 pdf; 2008:1\u20137."},{"key":"10.1016\/j.vaccine.2009.12.083_bib78","unstructured":"Opinions on medicines for use outside the European Union-Article 85. http:\/\/www emea europa eu\/htms\/human\/non_eu_epar\/background htm; 2009."},{"issue":"Jul (7)","key":"10.1016\/j.vaccine.2009.12.083_bib79","doi-asserted-by":"crossref","first-page":"e1000095","DOI":"10.1371\/journal.pmed.1000095","article-title":"The US Food and Drug Administration provides a pathway for licensing vaccines for global diseases","volume":"6","author":"Brennan","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2009.12.083_bib80","unstructured":"Fast Track Drug Development Programs: Designation and Review Programs: SOPP 8414. http:\/\/www fda gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/ProceduresSOPPs\/ucm073515 htm; 2009."},{"key":"10.1016\/j.vaccine.2009.12.083_bib81","series-title":"Guidance for industry: fast track drug development programs\u2014designation, development, and application review","year":"2009"},{"key":"10.1016\/j.vaccine.2009.12.083_bib82","unstructured":"Guidance for Industry: Tropical Disease Priority Review Vouchers. http:\/\/www fda gov\/OHRMS\/DOCKETS\/98fr\/FDA-2008-D-0530-gdl pdf; 2009 Draft Guidance."},{"issue":"Aug (8)","key":"10.1016\/j.vaccine.2009.12.083_bib83","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1371\/journal.pmed.0040252","article-title":"Development of new tuberculosis vaccines: a global perspective on regulatory issues","volume":"4","author":"Brennan","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2009.12.083_bib84","unstructured":"African Vaccine Regulatory Forum (AVAREF). http:\/\/www who int\/immunization_standards\/vaccine_regulation\/africa_network\/en\/index html; 2009."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10000198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10000198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T21:50:07Z","timestamp":1544737807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":84,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0264410X10000198"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.12.083","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}